Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
The ability to simultaneously track individual variants longitudinally via liquid biopsy is essential to further our understanding of tumor biology and its dynamic response to therapy. Personalis has developed a patented variant-tracking technology, which allows you to track and annotate individual variants over the whole evolution of a cancer patient’s trajectory in a single assay design.
Variants tracked in the blood are derived from those detected in the tissue, as well as a highly curated panel of Guideline-and pharma-driven mutations including driver mutations to inform initial therapy, and de novo resistance mutations, as shown in Figure 1. This ability to comprehensively measure variants across a patient’s sample affords you with unprecedented insights into a patient’s cancer evolution.
Figure 1: Our proprietary approach sequences a single panel consisting of MRD content, tumor-informed variant tracking, and fixed clinical variant tracking content. WGS is performed on patient tumor and normal samples. Up to 1800 targets are selected for MRD, up to 400 targets from exonic regions, and 2130 SNVs from curated fixed content.
Following therapeutic or surgical intervention, a patient’s molecular profile may evolve in response to a number of clinical factors. With Personalis variant tracking, you can monitor these changes to better understand therapy resistance, or the need for therapy modulation.
Figure 2: The ability to simultaneously detect MRD and variants from a single assay provides a power tool for navigating patient treatment and trial enrollment decisions.
In the figure above, the dark green line depicts tumor burden as a function allele frequency and time, with the limit of detection (LOD) of MRD tests noted on the right y-axis. The red, purple, and black lines represent the presence (dotted line) and detection (solid line) of new variants at defined variant allele frequency (VAF, left y-axis). With VariNTrack, investigators and clinicians can use these variants to identify new patient cohorts, further manage patient disease with additional, second line therapies. For our neoantigen customers, tracking putative neoantigens at the DNA level, and finally understanding resistance mutations.
